Other function: development of IL1RAP antibodies targeting AML CS

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201400030C
Awardee
Awarding agency
Obligated
$223,524

Award facts

Opportunity
  • N43CO4100527 Solicitation number
Contract value 100% obligated
$223,524.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 27 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
San Carlos, CA 94070, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 1 · Development of IL1RAP antibodies targeting AML CS $0
Original award $223,524

About this award

This is a definitive contract awarded by the National Cancer Institute, a civilian agency of the U.S. government, to Cellerant Therapeutics, Inc. for the development of IL1RAP antibodies targeting acute myeloid leukemia (AML) cancer stem cells. The contract has a firm fixed price of $223,524.00 and a completion date of August 11, 2015. This contract is not designated as a set-aside. The purpose of the contract is to support the development of these antibodies, which may contribute to the agency's efforts to advance cancer research and treatment.

Quick answers

Who was awarded contract HHSN261201400030C?

HHSN261201400030C was awarded to Cellerant Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 12, 2014.

How much is contract HHSN261201400030C worth?

The government has obligated $223,524 on HHSN261201400030C.

Was contract HHSN261201400030C competed?

The extent of competition for HHSN261201400030C was full and open competition. The government received 27 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award